Joe D. Cohen

发表

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

Kwaku Poku Asante, M. Tanner, K. Marsh, 2012, The New England journal of medicine.

Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine

O. Doumbo, M. Thera, W. Blackwelder, 2017, PloS one.

Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis.

R. Coler, S. Reed, Joe D. Cohen, 2009, FEMS immunology and medical microbiology.

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

Inacio Mandomando, Bart Spiessens, Mateu Espasa, 2004, The Lancet.

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen.

V. A. Stewart, M. Demoitié, Joe D. Cohen, 2008, Vaccine.

Update on the clinical development of candidate malaria vaccines.

D. Carucci, Joe D. Cohen, A. Hill, 2004, The American journal of tropical medicine and hygiene.

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial

F. Spertini, M. Demoitié, M. Cavassini, 2014, AIDS.

Isolation and characterization of a maltose transport mutant in the yeast Saccharomyces cerevisiae

Joe D. Cohen, J. Marmur, M. Goldenthal, 1983, Current Genetics.

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.

V. A. Stewart, Janet Wittes, J. Wittes, 2007, Vaccine.

Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP142) administered intramuscularly with adjuvant system AS01

W. Otieno, L. Otieno, Nekoye Otsyula, 2013, Malaria Journal.

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.

Joe D. Cohen, O. Ofori-Anyinam, C. Ockenhouse, 2006, Vaccine.

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine.

J. Haynes, Joe D. Cohen, C. Ockenhouse, 2003, Molecular and biochemical parasitology.

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

Joe D. Cohen, E. Angov, S. Pichyangkul, 2004, Vaccine.

A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults

M. Demoitié, S. Gatchalian, Joe D. Cohen, 2013, Journal of Clinical Immunology.

Evaluation of the Safety and Immunogenicity of Two Antigen Concentrations of the Mtb72F/AS02A Candidate Tuberculosis Vaccine in Purified Protein Derivative-Negative Adults

M. Demoitié, W. Ballou, Joe D. Cohen, 2010, Clinical and Vaccine Immunology.

Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein1

S. Hoffman, D. Carucci, P. de la Vega, 2004, The Journal of Immunology.

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

S. Hoffman, D. Carucci, Joe D. Cohen, 2004, Vaccine.

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

Joe D. Cohen, O. Ofori-Anyinam, P. Moris, 2009, Human vaccines.

Protection against Development of Otitis Media Induced by Nontypeable Haemophilus influenzae by Both Active and Passive Immunization in a Chinchilla Model of Virus-Bacterium Superinfection

Joe D. Cohen, L. Bakaletz, Y. Lobet, 1999, Infection and Immunity.

Information for Clinical Social Work Practice: A Potential Solution

G. Holden, G. Rosenberg, K. Barker, 2011, Clinical Social Work Journal.

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

Conor P. Cahill, M. Demoitié, L. Otieno, 2009, PloS one.

Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.

Q. Bassat, J. Sacarlal, P. Aide, 2008, Vaccine.

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.

M. Demoitié, K. Marsh, C. Drakeley, 2008, The New England journal of medicine.

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.

V. A. Stewart, M. Demoitié, Joe D. Cohen, 2008, Vaccine.

Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone

V. A. Stewart, M. Demoitié, Joe D. Cohen, 2007, Infection and Immunity.

Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.

V. A. Stewart, Joe D. Cohen, S. Pichyangkul, 2006, Vaccine.

Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial

O. Doumbo, M. Thera, W. Blackwelder, 2013, PloS one.

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria

K. Marsh, A. Olotu, P. Bejon, 2011, PloS one.

From the circumsporozoite protein to the RTS,S/AS candidate vaccine

V. Nussenzweig, Joe D. Cohen, A. Leach, 2010, Human vaccines.

Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naïve and Malaria-Exposed Individuals

D. Carucci, K. Marsh, T. Lang, 2006, Infection and Immunity.

Recombinant Protein Immunization with Malaria DNA and Cell and Antibody Responses by Sequential T + and CD4 + Induction in Humans of CD8

Patricia De la Vega, S. Hoffman, D. Carucci, 2004 .

Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial

Q. Bassat, J. Sacarlal, P. Aide, 2010, PloS one.

Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

Kwaku Poku Asante, M. Demoitié, S. Owusu-Agyei, 2009, PloS one.

Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications.

O. Doumbo, M. Thera, W. Blackwelder, 2013, The Journal of infectious diseases.

A field trial to assess a blood-stage malaria vaccine.

O. Doumbo, M. Thera, W. Blackwelder, 2011, The New England journal of medicine.

Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

Q. Bassat, J. Sacarlal, P. Aide, 2009, PloS one.

Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D

M. Demoitié, S. Agnandji, B. Lell, 2011, PloS one.

Malaria Vaccine of Tanzanian Children with the RTS,S/AS01 with NK Cell Responses after Immunization Antigen-Specific IL-2 Secretion Correlates

C. Drakeley, P. Bejon, Joe D. Cohen, 2012 .

Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells

Joe D. Cohen, O. Ofori-Anyinam, P. Moris, 2011, PloS one.

Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial

O. Doumbo, D. Thompson, M. Thera, 2010, PloS one.

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

V. A. Stewart, J. Wittes, M. Thera, 2005, Vaccine.

Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.

M. Demoitié, Joe D. Cohen, O. Ofori-Anyinam, 2013, American journal of respiratory and critical care medicine.

Impact of RTS,S/AS02A and RTS,S/AS01B on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial

Joe D. Cohen, A. Leach, M. Lievens, 2009, PloS one.

Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

V. A. Stewart, S. D. de Vlas, Joe D. Cohen, 2009, PloS one.

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02

A. Thomas, Joe D. Cohen, O. Ofori-Anyinam, 2008, PloS one.

Phase Ii, Randomized Trial to Assess the Safety and Immunogenicity of the Candidate Malaria Vaccines Rts,S/As02 and Rts,S/As01 When Given According to Different Vaccination Schedules in Children in Ghana

Kwaku Poku Asante, M. Demoitié, S. Owusu-Agyei, 2008 .

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

V. A. Stewart, J. Haynes, Joe D. Cohen, 2007, Vaccine.

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

Joe D. Cohen, N. Garçon, D. Heppner, 2003, Expert review of vaccines.

Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

Q. Bassat, M. Demoitié, J. Sacarlal, 2011, Vaccine.

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Pedro Alonso, Trudie Lang, Bernhards Ogutu, 2011, The New England journal of medicine.

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

N. Waters, W. Robinson, W. Ballou, 2016, The Journal of infectious diseases.

Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.

W. Ballou, Joe D. Cohen, O. Ofori-Anyinam, 2014, Vaccine.

Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial

Conor P. Cahill, J. Sacarlal, J. Aponte, 2007, Trials.

Five year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

K. Bojang, Joe D. Cohen, A. Leach, 2009, Human vaccines.

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

Q. Bassat, M. Demoitié, J. Sacarlal, 2007, The Lancet.

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

Q. Bassat, C. Menéndez, J. Sacarlal, 2005, The Lancet.

Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya

V. A. Stewart, W. Ripley Ballou, Janet Wittes, 2009, PloS one.

School-Wide Behavioral Support: Starting the Year Off Right

Robert H. Horner, George Sugai, Joe D. Cohen, 1997 .

A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

A. Hill, K. Bojang, B. Greenwood, 2004, Nature Medicine.

Prevention of Disease Induced by a Partially Heterologous AIDS Virus in Rhesus Monkeys by Using an Adjuvanted Multicomponent Protein Vaccine

D. Watkins, D. Montefiori, J. Heeney, 2003, Journal of Virology.

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

D. Conway, K. Bojang, B. Greenwood, 2001, The Lancet.

53 – Malaria vaccines

Joe D. Cohen, W. Ballou, Joe D. Cohen, 2013 .

Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver‐stage antigen‐3‐derived long synthetic peptides

Joe D. Cohen, C. Blanc, S. Herrera, 2008, European journal of immunology.

Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ1

W. Ripley Ballou, Joe D. Cohen, W. Ballou, 2003, The Journal of Immunology.

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

Joshua D. Hartzell, W. Ballou, Joe D. Cohen, 2016, PLoS neglected tropical diseases.

Heterologous Prime-Boost Regimens with a Recombinant Chimpanzee Adenoviral Vector and Adjuvanted F4 Protein Elicit Polyfunctional HIV-1-Specific T-Cell Responses in Macaques

Joe D. Cohen, C. Lorin, M. Koutsoukos, 2015, PloS one.

Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites.

E. Winzeler, V. Nussenzweig, Joe D. Cohen, 2011, Vaccine.

Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.

Kwaku Poku Asante, M. Tanner, S. Agnandji, 2011, The Lancet. Infectious diseases.

Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum

M. Demoitié, Joe D. Cohen, E. Jongert, 2012, Malaria Journal.

Development of the RTS,S/AS Vaccine Candidate from Concept to Phase III

Joe D. Cohen, A. Leach, J. Vekemans, 2011 .

Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine

C. Drakeley, P. Bejon, J. Lusingu, 2012, The Journal of Immunology.

Phase Iib, Randomized, Double-Blind Trial to Assess the Efficacy, Safety and Immunogenicity of the Candidate Malaria Vaccine Rts,S/As01 in Kenyan and Tanzanian Children

M. Demoitié, K. Marsh, C. Drakeley, 2008 .

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.

V. A. Stewart, W. Ballou, Joe D. Cohen, 2009, The Journal of infectious diseases.

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.

M. Tanner, H. Mshinda, M. Demoitié, 2008, The New England journal of medicine.

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys

R. Coler, S. Reed, Joe D. Cohen, 2009, Proceedings of the National Academy of Sciences.

The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study.

Pierre Vandepapelière, François Spertini, Erik Jongert, 2013, Tuberculosis.

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

W. Ballou, Joe D. Cohen, E. Jongert, 2015, PloS one.

Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children

K. Marsh, C. Drakeley, A. Olotu, 2011, The Journal of infectious diseases.

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

K. Marsh, C. Drakeley, A. Olotu, 2011, The Lancet. Infectious diseases.

PIPS one Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA 1 Malaria Vaccine Adjuvanted with Alhydrogel TM , Montanide ISA 720 or AS 02

A. Thomas, Joe D. Cohen, O. Ofori-Anyinam, 2017 .

Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.

Zhining Wang, Zhining Wang, Joe D. Cohen, 2010, The Journal of infectious diseases.

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

D. Webster, R. Sinden, P. Bejon, 2006, Vaccine.

Development of the RTS,S/AS malaria candidate vaccine.

Joe D. Cohen, A. Leach, J. Vekemans, 2009, Vaccine.

HLA-A*01-Restricted Cytotoxic T-Lymphocyte Epitope from the Plasmodium falciparum Circumsporozoite Protein

J. Sidney, A. Sette, S. Hoffman, 2001, Infection and Immunity.

Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3

L. BenMohamed, A. Thomas, Joe D. Cohen, 2000, Nature Medicine.

Protection against Development of Otitis Media Induced by Nontypeable Haemophilus influenzae by Both Active and Passive Immunization in a Chinchilla Model of Virus-Bacterium Superinfection

Joe D. Cohen, L. Bakaletz, Y. Lobet, 1999, Infection and Immunity.

Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.

Kwaku Poku Asante, M. Tanner, M. Demoitié, 2010, The Journal of infectious diseases.

Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.

Joe D. Cohen, J. Sattabongkot, C. Ockenhouse, 2013, Vaccine.

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.

M. Demoitié, W. Ballou, Joe D. Cohen, 2008, Vaccine.

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.

Marie-Claude Dubois, Janet Wittes, J. Wittes, 2007, Vaccine.

Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.

V. A. Stewart, Joe D. Cohen, K. Kester, 2006, Vaccine.

RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection

D. Conway, J. Sacarlal, J. Aponte, 2006, PLoS clinical trials.

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.

K. Bojang, Joe D. Cohen, A. Leach, 2005, Vaccine.

Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.

D. Conway, K. Bojang, B. Greenwood, 2003, The American journal of tropical medicine and hygiene.

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.

Kim A. Hatch, S. Kaufmann, S. Cole, 2005, Tuberculosis.

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

M. Tanner, H. Mshinda, S. Abdulla, 2013, Malaria Journal.

School-Wide Behavioral Support: Starting the

Joe D. Cohen, R. Horner, L. Nelson, 1997 .

Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial

V. A. Stewart, A. Dicko, O. Doumbo, 2008, PloS one.

Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.

Joe D. Cohen, S. Pichyangkul, P. Tongtawe, 2004, The American journal of tropical medicine and hygiene.

SAFETY AND IMMUNOGENICITY OF RTS , S + TRAP MALARIA VACCINE , FORMULATED IN THE AS 02 A ADJUVANT SYSTEM , IN INFANT RHESUS MONKEYS

Joe D. Cohen, S. Pichyangkul, P. Tongtawe, 2004 .

Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children

V. A. Stewart, J. Wittes, B. Ogutu, 2006, PLoS clinical trials.

Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum

M. Demoitié, Joe D. Cohen, E. Jongert, 2012, Malaria Journal.

T Cell Responses to the RTS,S/AS01E and RTS,S/AS02D Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children

Kwaku Poku Asante, S. Owusu-Agyei, D. Dosoo, 2011, PloS one.

Evaluation of the Safety and Immunogenicity of Two Antigen Concentrations of the Mtb72F/AS02 A Candidate Tuberculosis Vaccine in Puriﬁed Protein Derivative-Negative Adults (cid:1) †

M. Demoitié, Joe D. Cohen, O. Ofori-Anyinam, 2010 .

Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.

Joe D. Cohen, C. Mason, W. Ballou, 2006, The American journal of tropical medicine and hygiene.

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

V. A. Stewart, Joe D. Cohen, A. Hess, 2006, Vaccine.

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.

V. A. Stewart, Marie-Claude Dubois, In-Kyu Yoon, 2010, Vaccine.

A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults

M. Demoitié, S. Gatchalian, Joe D. Cohen, 2013, Journal of Clinical Immunology.

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.

Inácio Mandomando, Marie-Claude Dubois, Quique Bassat, 2009, The Journal of infectious diseases.

Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines

Joe D. Cohen, E. Jongert, M. Lievens, 2014, Human vaccines & immunotherapeutics.

Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children

K. Marsh, C. Drakeley, A. Olotu, 2010, PloS one.

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon

M. Demoitié, S. Agnandji, B. Lell, 2009, PloS one.

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

Joe D. Cohen, W. Ballou, K. Kester, 1997, The New England journal of medicine.

Vaccines Against Human Hookworm Disease

S. Hoffman, D. Vaughn, R. Brunham, 2004 .

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

G. Wortmann, Joe D. Cohen, R. Wirtz, 1998, The Journal of infectious diseases.

Preclinical Evaluation of the Safety and Immunogenicity of a Vaccine Consisting of Plasmodium falciparum Liver-Stage Antigen 1 with Adjuvant AS01B Administered Alone or Concurrently with the RTS,S/AS01B Vaccine in Rhesus Primates

V. A. Stewart, Joe D. Cohen, M. Fukuda, 2007, Infection and Immunity.